Maze Therapeutics Inc

Research Maze Therapeutics Inc (MAZE) on Bullrun: market cap USD 1.61B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMAZE
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 1.61B
• Financial periodFY2025
• Net income-USD 131.12M
• Free cash flow-USD 112.73M

Valuation Snapshot

latest market cap is USD 1.61B.

About Maze Therapeutics Inc

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease;

Frequently asked questions

What is Maze Therapeutics Inc's market cap?

Maze Therapeutics Inc's market capitalization is USD 1.61B.

What does Maze Therapeutics Inc do?

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.